retatrutide triple agonist glp-1 gip glucagon receptor Dual and Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Retatrutide Peptide – Triple Agonist

Participants receive close monitoring, and outcomes dont always translate perfectly into everyday care

With clinically meaningful weight loss and cardiovascular outcomes in patients with type 2 diabetes, GLP-1RAs were further assessed in patients with overweight or obesity without type 2 diabetes in the 2021 STEP-1 trial and 2022 SURMOUNT-1 trial

Louis Aronne, director of comprehensive weight control center, Weill Cornell Medicine

We have never had a category of medication which has tempted 1.25 million people to say, actually, Im going to forgo the NHS, Im going to look after myself and self-medicate. He estimates that 80% of GLP-1 users are women and a fifth are men, even though the obesity split in the population is 50-50

Diabetes Care 2023;46:384-90.PubMed 108

31 If solid foods are difficult, nutrient-dense protein shakes or meal replacement shakes can be a temporary option